Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 290

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Open access
Bachy, Emmanuel, Seymour, John F., Feugier, Pierre, Offner, Fritz, López-Guillermo, Armando, Belada, David, Xerri, Luc, Catalano, John V., Brice, Pauline, Lemonnier, François, Martin, Alejandro, Casasnovas, Olivier, Pedersen, Lars M., Dorvaux, Véronique, Simpson, David, Leppa, Sirpa, Gabarre, Jean, da Silva, Maria G., Glaisner, Sylvie, Ysebaert, Loic, Vekhoff, Anne, Intragumtornchai, Tanin, Le Gouill, Steven, Lister, Andrew, Estell, Jane A., Milone, Gustavo, Sonet, Anne, Farhi, Jonathan, Zeuner, Harald, Tilly, Hervé, Salles, Gilles · 2019 · Journal of Clinical Oncology

Abstract

PURPOSE: The PRIMA study (ClinicalTrials.gov identifier: NCT00140582 ) established that 2 years of rituximab maintenance after first-line immunochemotherapy significantly improved progression-free survival (PFS) in patients with follicular lymphoma compared with observation. Here, we report the final PFS and overall survival (OS) results from the PRIMA study after 9 years of follow-up and provide a final overview of safety. METHODS: Patients (> 18 years of age) with previously untreated high–tumor-burden follicular lymphoma were nonrandomly assigned to receive one of three immunochemotherapy induction regimens. Responding patients were randomly assigned (stratified by induction regimen, response to induction treatment, treatment center, and geographic region) 1:1 to receive 2 years of rituximab maintenance (375 mg/m 2, once every 8 weeks), starting 8 weeks after the last induction treatment, or observation (no additional treatment). All patients in the extended follow-up provided their written informed consent (data cutoff: December 31, 2016). RESULTS: In total, 1,018 patients completed induction treatment and were randomly assigned to rituximab maintenance (n = 505) or observation (n = 513). Consent for the extended follow-up was provided by 607 patients (59.6%) of 1,018 (rituximab maintenance, n = 309; observation, n = 298). After data cutoff, median PFS was 10.5 years in the rituximab maintenance arm compared with 4.1 years in the observation arm (hazard ratio, 0.61; 95% CI, 0.52 to 0.73; P < .001). No OS difference was seen in patients randomly assigned to rituximab maintenance or observation (hazard ratio, 1.04; 95% CI, 0.77 to 1.40; P = .7948); 10-year OS estimates were approximately 80% in both study arms. No new safety signals were observed. CONCLUSION: Rituximab maintenance after induction immunochemotherapy provides a significant long-term PFS, but not OS, benefit over observation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.19.01073

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

Metadata

Authors
Bachy, E., Seymour, J. F., Feugier, P., Offner, F., López-Guillermo, A., Belada, D., Xerri, L., Catalano, J. V., Brice, P., Lemonnier, F., Martin, A., Casasnovas, O., Pedersen, L. M., Dorvaux, V., Simpson, D., Leppa, S., Gabarre, J., da Silva, M. G., Glaisner, S., Ysebaert, L., Vekhoff, A., Intragumtornchai, T., Le Gouill, S., Lister, A., Estell, J. A., Milone, G., Sonet, A., Farhi, J., Zeuner, H., Tilly, H., & Salles, G.
Venue
Journal of Clinical Oncology
Published
2019-11-01
Volume
37
Issue
31
Pages
2815-2824
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2963759094
Cited by
290
References
29
FWCI
21.75
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.